Cemiplimab 生物类似药, PD-1 单克隆抗体-Cemiplimab Biosimilar, PD-1 Monoclonal Antibody代理/参数/厂家-二抗-开云·官方站线上登录平台入口

PRODUCT CENTER

二抗

开云·官方站线上登录平台入口_开云(中国)

当前位置：开云·官方站线上登录平台入口 > 开云·官方站线上登录平台入口_开云(中国) > 免疫学产品 > 二抗

背景资料: Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab.nnPD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).nnCemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response.nnBinding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.

保存建议: Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.

其他: ProMab 生物技术公司通过整合生物信息学、分子生物学、蛋白质表达、纯化技术、基因克隆、微生物学和免疫学，利用新型高通量技术开发重组蛋白、抗体和工程细胞系并将其商业化。专注于免疫治疗领域，特别是 CAR-T/NK 细胞技术。ProMab 还开发了一种新型的 mRNA 脂质纳米颗粒（mRNA-LNP）平台，用于即用型试剂和定制研究服务，以推进现有产品并扩展到更多的研究领域。